CurrentUnitedHealthcarePolicy CS029NM.C

Cytological Examination Breast Fluids Cancer Screening Nm Cs

State-specific (New Mexico) UnitedHealthcare medical policy on cytological examination of breast ductal fluids (breast ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) for breast cancer screening, diagnosis, or as alternative tools to guide surgery. Defines coverage rationale (not medically necessary) and lists applicable CPT code reference.

Policy Summary

PayerUnitedHealthcare

PolicyCytological Examination Breast Fluids for Cancer Screening or Diagnosis (for New Mexico Only)

Policy CodePolicy CS029NM.C

Change TypeSupporting information updated

Effective DateAug 1, 2025

Next Review Date

Key ActionThis medical policy applies only to the state of New Mexico; verify federal, state, or contractual requirements which may supersede this policy.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

3Procedures declared not medically necessary

1Reference CPT code listed

NMState applicability

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

State-specific (New Mexico) policy CS029NM.C effective 08/01/2025 (last reviewed 08/01/2025) declares cytological examination of breast ductal fluids (ductal lavage, nipple aspirate fluid, and fiberoptic ductoscopy) not medically necessary for breast cancer screening, diagnosis, or as alternatives to guide surgery. Rationale: studies show low sensitivity, a high rate of inadequate or inconclusive samples, and no evidence of reduced breast cancer mortality with these techniques; practice guidelines (NCCN) do not recommend ductal lavage.

Medically Necessary / Not Medically Necessary Criteria

Medically Necessary / Not Medically Necessary

The following are unproven and not medically necessary for use in breast cancer screening, breast cancer diagnosis, or as alternatives to guide surgery:

ALL of the following

Breast ductal lavage
Unproven and not medically necessary due to insufficient evidence of efficacy; low sensitivity, high inconclusive results, no evidence of mortality benefit.
Breast ductal fluid aspiration and cytology (including nipple aspirate fluid)
Unproven and not medically necessary due to limitations in diagnostic accuracy, sample adequacy, and lack of impact on clinical outcomes; high sample inadequacy rates and poor sensitivity.
Fiberoptic ductoscopy (with or without ductal lavage)
Unproven and not medically necessary due to limited high-quality evidence that it improves detection rates, stage at diagnosis, or mortality; technically challenging and limited ductal visualization.

These procedures are considered unproven and not medically necessary for screening, diagnosis, or as alternatives to guide surgery. The policy notes limited diagnostic accuracy and sample adequacy issues, including low sensitivity and high rates of inconclusive or inadequate specimens, and insufficient evidence that their use improves clinical outcomes or mortality.

Provider Actions

Prior Authorization

Prior authorization implication

Services identified as unproven and not medically necessary are subject to denial under benefit coverage rules; check plan-specific preauthorization requirements and benefit contracts.

Documentation Required

State-specific applicability

This medical policy applies only to the state of New Mexico; verify federal, state, or contractual requirements which may supersede this policy.

Billing Rule

Code usage guidance

Listing of CPT code(s) is for reference only and does not imply coverage or reimbursement; inclusion does not guarantee claim payment.

19499

Background & Evidence

Cytological examination methods obtain epithelial cells from breast ducts via ductal lavage (inserting a microcatheter into ducts through the nipple), nipple aspiration (noninvasive or fine-needle aspiration), or fiberoptic ductoscopy (direct visualization with a thin endoscope, sometimes combined with lavage or biopsy). Evidence across studies shows limitations: low sensitivity, high inadequate sample rates, and insufficient data that these techniques improve detection of cancer in a way that changes outcomes or mortality. Practice guidelines reflect these limitations: NCCN does not recommend ductal lavage, and nipple smear cytology is not routinely recommended for nipple discharge without palpable symptoms.

Measure	Value
NAF sensitivity (meta-analysis Jiwa et al. 2021)	0.64 (95% CI 0.62-0.66)
NAF specificity (Jiwa et al. 2021)	0.97 (95% CI 0.97-0.98)
DL sensitivity example (Khan et al. 2004)	43% (when marked atypia/malignant defined positive); variable by definition
Ductoscopy pooled sensitivity (Waaijer et al. 2016)	94% (95% CI 88-97) with low specificity (47%)

Ductal lavage (DL): Procedure inserting a microcatheter into breast ducts via the nipple to remove ductal fluid for cytologic analysis.

Nipple aspirate fluid (NAF): Fluid obtained noninvasively or via fine-needle aspiration from the nipple for cytologic or biomarker analysis.

Fiberoptic ductoscopy (FDS): Endoscopic visualization of breast ducts with a thin endoscope, sometimes combined with lavage or biopsy.